

ASX Announcement

23 July 2025

Appointment and Resignation of Company Secretary

Oncosil Medical Limited (ASX: OSL) advises, in accordance with ASX Listing Rule 3.16.1 that Mr Nathan Kim-liung Jong has resigned as Company Secretary, effective 23 July 2025.

The Board thanks Mr Jong for his valuable contribution to the Company and wishes him well in his future endeavors.

The Company is pleased to announce the appointment of Ms Olga Smejkalova as Company Secretary, effective 23 July 2025. In accordance with Listing Rule 12.6, Ms Olga Smejkalova is the person responsible for communication with the ASX regarding ASX Listing Rule matters. Ms Smejkalova brings extensive experience in corporate governance and compliance, and the Board looks forward to her contribution in this role.

Authorisation & Additional Information

This announcement was authorised by the Board of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Ms Olga Smejkalova Company Secretary E: o.smejkalova@acclime.com	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699
-------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/